Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.52M | -2.33M | -501.00K | 4.52M | -25.85M |
| Total Depreciation and Amortization | 3.93M | 3.78M | -16.28M | 3.41M | 9.66M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.82M | 11.52M | 27.91M | 4.37M | 30.53M |
| Change in Net Operating Assets | -19.36M | 13.97M | 11.50M | 8.51M | -20.38M |
| Cash from Operations | -22.13M | 26.93M | 22.63M | 20.82M | -6.04M |
| Capital Expenditure | -12.46M | -7.18M | -14.83M | -9.26M | -4.74M |
| Sale of Property, Plant, and Equipment | 7.00K | 5.00K | 19.00K | 12.00K | 9.00K |
| Cash Acquisitions | -- | -1.00K | 0.00 | -18.73M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.36M | 16.01M | -3.57M | -401.00K | -17.70M |
| Cash from Investing | -25.80M | 8.83M | -18.39M | -28.38M | -22.43M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -24.00K | -27.00K | -31.00K | -31.00K | -26.00K |
| Issuance of Common Stock | 1.59M | 2.81M | 297.00K | 531.00K | 988.00K |
| Repurchase of Common Stock | -6.60M | -7.37M | -1.19M | -589.00K | -2.52M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | 190.00K | -- |
| Cash from Financing | -5.03M | -4.59M | -919.00K | 101.00K | -1.55M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.97M | 31.17M | 3.32M | -7.46M | -30.02M |